Drug Profile
Research programme: decoy oligonucleotide therapeutics - AnGes
Alternative Names: NF-kappa-B/E2F decoy oligonucleotide; NF-kappa-B/Ets decoy oligonucleotideLatest Information Update: 03 Jan 2020
Price :
$50
*
At a glance
- Originator AnGes MG
- Developer AnGes; Osaka University
- Class Oligonucleotides
- Mechanism of Action E2F transcription factor inhibitors; Matrix metalloproteinase inhibitors; NF-kappa B inhibitors; Proto-oncogene-protein-c-ets inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Vascular disorders